Galapagos publishes 2006 Prospectus and announces management change

    This press release constitutes a supplement to the Galapagos 2006
Prospectus

Mechelen, Belgium;  30 March  2007 -  Galapagos NV  (Euronext &  LSE:
GLPG) announces the publication of its 2006 Prospectus in  connection
with the share  issues resulting from  the all-share acquisitions  of
Inpharmatica and ProSkelia and the  ¤31 million private placement  in
December 2006.   Galapagos also  announces the  resignation of  David
Smith  as  Chief  Financial  Officer  and  the  appointment  of   Leo
Steenbergen as Chief Financial Officer, effective 1 June 2007.  David
Smith will continue  to serve Galapagos  as CFO until  June and  will
assist in the transition process.

Prospectus

Galapagos' 2006 Prospectus (consisting of a Registration Document,  a
Transaction Note and a Summary)  was approved by the Belgian  Banking
Finance and Insurance Commission (BFIC-CBFA) on 20 March 2007 and  by
the Alternative Investment Market of the London Stock Exchange on  21
March 2007.    On 26 March 2007,  application was made for  5,483,913
 shares in Galapagos NV to be  admitted to trading on the AIM  market
of the  London Stock  Exchange.   On the  basis of  this  Prospectus,
Galapagos has obtained the authorization  for the listing of  maximum
7,025,863 shares on  Eurolist of  Euronext Brussels  and of  Euronext
Amsterdam, as well as on London  AiM, effective as of 30 March  2007,
of which 5,483,913  shares have already  been issued on  the date  of
this supplement, with  the remainder to  be issued in  April and  May
2007.  The newly issued and to be issued shares in question relate to
a number of  transactions Galapagos completed  in December 2006:  the
acquisition of Inpharmatica Ltd on 5 December 2006 (maximum 2,165,532
newly issued and to be issued  shares), the private placement of  ¤31
million on 22 December 2006  (3,463,683 newly issued shares) and  the
acquisition of ProSkelia  SASU also  on 22  December 2006  (1,396,648
newly issued shares).  Further  capital increases in relation to  the
acquisition of Inpharmatica Ltd. will be made public via  supplements
to the Prospectus in  which the exact number  of newly issued  shares
will be indicated.  The newly issued shares rank pari passu with  the
Company's existing shares and will be tradeable on Euronext  Brussels
and Euronext Amsterdam and on AiM  starting today.  Shares issued  in
connection with  the  Inpharmatica acquisition  remain  under  lockup
until 10 May  2007, while  those issued to  ProStrakan in  connection
with the ProSkelia acquisition remain under lockup until 22  December
2007.

Change in management

David Smith,  who has  served Galapagos  as Chief  Financial  Officer
since February 2006,  will be  leaving the  Company in  June 2007  to
pursue  his  career  further  with  UK  based  Cambridge   University
Hospitals NHS Foundation Trust.   David will be  replaced by Mr.  Leo
Steenbergen who has accepted the CFO position effective as of 1  June
2007.

Leo Steenbergen (54) was most recently Chief Financial Officer and  a
member of the Management Board of Telenet NV from January 2002  until
December 2006.  Under his management, the company was refinanced and,
in 2005, completed a successful Initial Public Offering on Euronext.
Prior to  joining Telenet,  Leo was  CEO of  IP Globalnet,  where  he
successfully restructured and  turned around operations,  and CFO  of
the Bekaert Group.  Leo worked from 1980 to 1997 for  Hewlett-Packard
Europe in various finance positions.

"I am very pleased to be joining  Galapagos as CFO, and I am  excited
about this opportunity.  Galapagos is  a remarkable  company with  an
excellent track  record  in  building a  biotech  leader,"  said  Leo
Steenbergen.   "I  look  forward  to  contributing  to  Galapagos  my
experience gained in working with high growth technology companies."

"Leaving Galapagos has been a  difficult decision, as I have  enjoyed
contributing to the success and  the growth of Galapagos and  helping
to shape the company into an integrated drug discovery business.  For
a combination of personal reasons, however, I wish to take my  career
in a  different direction,"  said David  Smith.   "Galapagos is  well
under way to becoming a leading European biotech company and is  well
positioned for its next phase of development and growth."

"David has made a much valued  contribution to Galapagos, and we  are
sorry that  he  has  elected  to  leave  Galapagos  and  the  biotech
industry.  We wish  him success in his  future endeavors," said  Onno
van de Stolpe, Chief Executive Officer of Galapagos. "We welcome  Leo
as his replacement; Leo's background and experience in high tech  and
high growth companies will be invaluable in aggressively growing  our
services  business  and  progressing  our  pipeline  of   therapeutic
compounds in bone and joint diseases towards entry into the clinic in
2008."


Financial Calendar 2007

Half Year Results 2007                                              8
August 2007
Full Year Results 2007                                              7
March 2008


Availability of documents

This press release  constitutes a  supplement to  the Galapagos  2006
Prospectus.  The English version of this supplement has been approved
by BFIC  on  27 March  2007.    This supplement,  together  with  the
Galapagos Registration Document 2006, the Transaction Note 2006,  and
the Summary,  constitute the  2006 Prospectus  for the  admission  to
listing of new Galapagos shares.

The     2006      Prospectus     is      available     online      at
www.glpg.com/investor/prospectus.htm.   The  electronic  versions  of
Galapagos'  2006  Company  report  and  Annual  brochure   (including
consolidated and non-consolidated accounts)  are available online  in
both            Dutch            and            English            at
www.glpg.com/investor/financial_reports.htm.  Printed versions of the
reports can be requested by e-mail: [e-mail], by phone: +32 15  34
29 00, and by fax: [phone].

This supplement is published  in English and  Dutch. The English  and
the Dutch versions have equal value.  Onno van de Stolpe assumes  the
responsibility for the  translation of  the English  version of  this
supplement into Dutch.


About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London
AiM: GLPG) is a drug discovery company with clinical and pre-clinical
programs in bone and joint diseases, cachexia, and menopausal hot
flashes.  Its division BioFocus DPI offers a full suite of
target-to-drug discovery products and services to pharmaceutical and
biotech companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates.  BioFocus DPI also provides adenoviral reagents for rapid
identification and validation of novel drug targets, compound
libraries for drug screening as well as chemogenomics and ADMET[1]
database products to select targets and compounds.  Galapagos
currently employs 450 people and operates facilities in eight
countries, with global headquarters in Mechelen, Belgium.  More
information about Galapagos and BioFocus DPI can be found at
www.glpg.com.
CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel. [phone]
[e-mail]


This  release  may  contain  forward-looking  statements,  including,
without  limitation,  statements  containing  the  words  "believes,"
"anticipates," "expects," "intends,"  "plans," "seeks,"  "estimates,"
"may," "will,"  "could," "stands  to," and  "continues," as  well  as
similar expressions.   Such  forward-looking statements  may  involve
known and unknown risks, uncertainties and other factors which  might
cause  the  actual  results,  financial  condition,  performance   or
achievements of  Galapagos, or  industry  results, to  be  materially
different from any historic or future results, financial  conditions,
performance  or   achievements   expressed   or   implied   by   such
forward-looking statements.  Given these uncertainties, the reader is
advised not  to  place any  undue  reliance on  such  forward-looking
statements.  These  forward-looking statements speak  only as of  the
date of publication of this document.  Galapagos expressly  disclaims
any obligation to update any such forward-looking statements in  this
document to  reflect  any  change in  its  expectations  with  regard
thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

[1] ADMET is the acronym for Absorption, Distribution, Metabolism,
Excretion, and Toxicity: Meeting parameters against these five
criteria is critical to the success of a pharmaceutical compound as a
drug.






Copyright © Hugin ASA 2007. All rights reserved.